Company Pipelines 2 articles

Company Pipelines maps the therapeutic or diagnostic assets a biotechnology company is advancing and how those programs fit together. Stage, indication, modality, lead programs, prioritization, overlap and portfolio concentration help explain development strategy and risk. The category is narrower than general company coverage because the pipeline itself is the unit of analysis; financing, corporate history or market performance belongs elsewhere unless it directly changes which assets are advanced or discontinued.

Biotechnology News & Analysis

October 2, 2026, 8:35 AM · 4 mins read

Novartis bets $7.8 billion on RNA drugs as Boehringer’s obesity hopes stumble

Novartis is putting up to $7.8 billion on the table for Abogen’s RNA therapies. Meanwhile, Boehringer Ingelheim and Zealand Pharma’s obesity drug failed to impress in a tough market.

Biotechnology News & Analysis

October 2, 2026, 2:27 AM · 4 mins read

AgroNetica moves gene-edited cacao closer to farms as disease crisis grows

AgroNetica is pushing a new gene-edited cacao that resists black pod disease. The company hopes this will protect chocolate supplies and change how the industry thinks about ethics and economics.